Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Compassionate Use Treatment Protocol I4V-MC-JAGA: Treatment of Conditions Expected to Benefit From JAK 1/2 Inhibition: CANDLE, CANDLE-Related Conditions, SAVI and Severe Juvenile Dermatomyositis

NCT01724580 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT01724580
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01724580 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Compassionate Use Treatment Protocol I4V-MC-JAGA: Treatment of Conditions Expected to Benefit From JAK 1/2 Inhibition: CANDLE, CANDLE-Related Conditions, SAVI and Severe Juvenile Dermatomyositis
Lead sponsor
Eli Lilly and Company
Phase
Expanded access
Overall status
Approved for marketing
Start date
Not reported
Completion date
Not reported
Enrollment
Not reported
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

aicardi-goutières syndrome (ags), chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature (candle), juvenile dermatomyositis (jdm), stimulator of interferon genes (sting)-associated vasculopathy with onset during infancy (savi)